2019

GT Gain Therapeutics SA

Follow us

  • LinkedIn Social Icon

TARGET GENE

GALC

TARGET ENZYME

Galactosylceramidase

PRIMARY

STORAGE

Galactosylsphingosine

SECONDARY

STORAGE

Alpha-synuclein

EPIDEMIOLOGY

1 : 100-250,000

UNMET MEDICAL NEED

No available treatment or cure

DEVELOPMENT

STAGE

Discovery

In vitro